Our previous pharmacokinetic studies revealed the considerably low oral bioavailability (2%, 50 mg/kg, Table S1) of WEL in rats, which resulted from the extensive first-pass metabolism of WEL in the gastrointestinal tract.
The objectives of the present study included (1) to identify through ultra-high-performance liquid chromatography/quadrupole time-of-flight mass spectrometry (UPLC/Q-TOF MS) and high-performance liquid chromatography-solid-phase extraction-nuclear magnetic resonance spectroscopy (HPLC-SPE-NMR) the WEL metabolites formed in rats following an oral administration of 50 mg/kg WEL; (2) to determine the uridine diphosphate-glucuronosyltransferases (UGTs) responsible for WEL glucuronidation using human liver microsomes (HLMs), human intestine microsomes (HIMs), human kidney microsomes (HKMs), and recombinant human UGT enzymes; and (3) to explore the possible mechanisms of WEL regioselective glucuronidation.
To test their catchability as well as growth, British researchers examined recaptures of tagged wels
in a small catch-and-release lake in England *.
Digital communication technology provider DRI Corporation (DRI) (Nasdaq:TBUS) announced on Wednesday that it has appointed Oliver Wels
as president of DRI Corporation, effective 25 March 2010.
Contact point(s): Holding Wels
Immobilien GmbH & Co.
Major organization : HOLDING WELS IMMOBILIEN GMBH & CO.
Implementing agency : Klinikum Wels